Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tetravalent blending VDV-2/CYD-1, 3, 4 Dengue · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Group 3 | EXPERIMENTAL | - |
| Group 4 | EXPERIMENTAL | - |
| Group 5 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero) | BIOLOGICAL | 0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105) |
| Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero) | BIOLOGICAL | 0.5 mL, Subcutaneous (SC) (Day 0 and Day 105) |
| Tetravalent CYD-1,2,3,4 Dengue (Vero) | BIOLOGICAL | 0.5 mL, Subcutaneous (SC) (Day 0 and Day 105) |
| JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero) | BIOLOGICAL | 0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105) |
Inclusion Criteria : * Healthy as determined by medical history, clinical examination, and biological safety parameters * Aged 18 to 45 years on the day of inclusion. * Informed consent form signed. * Able to attend all scheduled visits and to comply with all trial procedures * For a woman of child...
Tetravalent blending VDV-2/CYD-1,3,4 Dengue is an investigational monoclonal antibody being developed for the prevention of Dengue Virus infections, including Dengue Fever and Dengue Hemorrhagic Fever. It is a tetravalent vaccine formulation designed to target all four dengue virus serotypes. The drug is currently in Phase 2 clinical development.
Tetravalent blending VDV-2/CYD-1,3,4 Dengue is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and immunogenicity of this dengue vaccine candidate.
Tetravalent blending VDV-2/CYD-1,3,4 Dengue is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its safety and immunogenicity in healthy adults, with one completed Phase 2 trial involving 154 participants.
Tetravalent blending VDV-2/CYD-1,3,4 Dengue has been studied in one clinical trial, identified as NCT00740155. This Phase 2 trial, titled 'Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults,' was completed and enrolled 154 participants in Mexico. The trial was randomized and active-controlled, evaluating the vaccine in healthy volunteers aged 18 years and older.
Tetravalent blending VDV-2/CYD-1,3,4 Dengue is a tetravalent vaccine formulation that combines the VDV-2 component with CYD-1, CYD-3, and CYD-4 components. It is designed to elicit an immune response against all four dengue virus serotypes, potentially providing broad protection against dengue disease. The vaccine is administered to stimulate the production of neutralizing antibodies.